Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part II
- 1 August 2009
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 48 (8) , 489-516
Abstract
Part I of this article, which appeared in the previous issue of the Journal, reviewed calcineurin inhibitors —ciclosporin and tacrolimus. In part II, we review the pharmacokinetics and therapeutic drug monitoring of mycophenolate and mammalian target of rapamycin inhibitors — sirolimus and everolimus — in thoracic transplantation, and we provide an overall discussion and suggest various areas for future study.Keywords
This publication has 148 references indexed in Scilit:
- Cyclosporine C2 Target Levels and Acute Cellular Rejection After Lung TransplantationThe Journal of Heart and Lung Transplantation, 2006
- Advantages of C2 Monitoring to Avoid Acute Rejection in Pediatric Heart Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2006
- A Randomized, Controlled Trial of C0- Vs C2-guided Therapeutic Drug Monitoring of Cyclosporine in Stable Heart Transplant PatientsThe Journal of Heart and Lung Transplantation, 2005
- Clinical Experience With Certican® (Everolimus) in Maintenance Heart Transplant Patients at the Medical University of ViennaThe Journal of Heart and Lung Transplantation, 2005
- Cyclosporine C2 monitoring improves renal dysfunction after lung transplantationThe Journal of Heart and Lung Transplantation, 2004
- Clinical Pharmacokinetics of EverolimusClinical Pharmacokinetics, 2004
- Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant PatientsClinical Pharmacokinetics, 2004
- Clinical Pharmacokinetics of SirolimusClinical Pharmacokinetics, 2001
- Methods for Clinical Monitoring of Cyclosporin in Transplant PatientsClinical Pharmacokinetics, 2000
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998